Ignite Creation Date:
2024-10-26 @ 3:35 PM
Last Modification Date:
2024-10-26 @ 3:35 PM
Study NCT ID:
NCT06509360
Status:
RECRUITING
Last Update Posted:
None
First Post:
2023-09-01
Brief Title:
How do You Feelee Emotion-based Smartphone App in the Forensic Outpatient Setting
Sponsor:
None
Organization:
None
Study Overview
Official Title:
How do You Feelee Does an Ordinary Question a Day Supports Youth in a Forensic Outpatient Setting to Become More Emotional Balanced A Multiple Case Experimental Design
Status:
RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This intervention study aims to explore the addition of the Feelee app using active emoji data with passive behavioral data through phone sensing in treatment as usual for adolescents in the forensic outpatient setting
Participants will use Feelee for 4 weeks which means specifying an emoji each day and collecting the passive data on the background The collected active and passive data will be discussed through the clinicians during the participants weekly treatment sessions
Participants will use Feelee for 4 weeks which means specifying an emoji each day and collecting the passive data on the background The collected active and passive data will be discussed through the clinicians during the participants weekly treatment sessions
Detailed Description:
Participants will be subjected to a ABA baseline design including a 2-weeks baseline phase A 4-weeks intervention phase B and 2-weeks follow-up phase
During the baseline phase A participants will fill in a daily questionnaire that measures different aspects of their emotion regulation skills The use of the Feelee app is not allowed yet After 2-weeks the intervention phase starts meaning participants will use the Feelee app every day during a 4-weeks period The use of the Feelee app includes specifying an emoji and collecting the passive data on the background Furthermore the collected active and passive data will be discussed through the clinicians during the participants weekly treatment sessions Participants will also be continuing to complete the daily questionnaire After 4-weeks the follow-up phase starts Participants need to remove the Feelee app and will follow their treatment as usual However participants still need to complete the daily questionnaire After 2-weeks the follow-up phase and main study part has ended
Throughout the ABA baseline pre-measurement T0 post-measurement T1 follow-up measurement Tf1 will be conducted before and after the intervention and during follow-up Last a 3-months follow-up will be conducted to identify possible long-term effects
During the baseline phase A participants will fill in a daily questionnaire that measures different aspects of their emotion regulation skills The use of the Feelee app is not allowed yet After 2-weeks the intervention phase starts meaning participants will use the Feelee app every day during a 4-weeks period The use of the Feelee app includes specifying an emoji and collecting the passive data on the background Furthermore the collected active and passive data will be discussed through the clinicians during the participants weekly treatment sessions Participants will also be continuing to complete the daily questionnaire After 4-weeks the follow-up phase starts Participants need to remove the Feelee app and will follow their treatment as usual However participants still need to complete the daily questionnaire After 2-weeks the follow-up phase and main study part has ended
Throughout the ABA baseline pre-measurement T0 post-measurement T1 follow-up measurement Tf1 will be conducted before and after the intervention and during follow-up Last a 3-months follow-up will be conducted to identify possible long-term effects
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None